Literature DB >> 12939433

Low levels of ventricular CSF orexin/hypocretin in advanced PD.

X Drouot1, S Moutereau, J P Nguyen, J P Lefaucheur, A Créange, P Remy, F Goldenberg, M P d'Ortho.   

Abstract

The origins of excessive daytime sleepiness in Parkinson disease (PD) are unclear. The authors hypothesize that orexin neurons, a recently identified wake promoting system, could contribute to its pathophysiology. They measured orexin-A/hypocretin-1 concentration in ventricular CSF in 19 parkinsonian patients and compared it with neurologic controls. Orexin levels were lower in patients and decreased with the severity of the disease. The authors suggest that orexin neurons contribute to daytime sleepiness in late stage PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939433     DOI: 10.1212/01.wnl.0000078194.53210.48

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  Reduced hypocretin (orexin) levels in dementia with Lewy bodies.

Authors:  Stephanie Lessig; Kiren Ubhi; Douglas Galasko; Anthony Adame; Emiley Pham; Kelly Remidios; Michael Chang; Lawrence A Hansen; Eliezer Masliah
Journal:  Neuroreport       Date:  2010-08-04       Impact factor: 1.837

2.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

3.  Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.

Authors:  W G Ondo; R Fayle; F Atassi; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

4.  Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.

Authors:  Sven Pålhagen; Hongshi Qi; Björn Mårtensson; Jan Wålinder; Ann-Kathrine Granérus; Per Svenningsson
Journal:  J Neurol       Date:  2009-10-21       Impact factor: 4.849

Review 5.  Are sleep disturbances preclinical markers of Parkinson's disease?

Authors:  Altair B dos Santos; Kristi A Kohlmeier; George E Barreto
Journal:  Neurochem Res       Date:  2014-11-30       Impact factor: 3.996

6.  Daytime REM sleep in Parkinson's disease.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Parkinsonism Relat Disord       Date:  2012-08-29       Impact factor: 4.891

Review 7.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

Review 8.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

9.  The wake-promoting effects of hypocretin-1 are attenuated in old rats.

Authors:  Stephen R Morairty; Jonathan Wisor; Kristy Silveira; William Sinko; Thomas S Kilduff
Journal:  Neurobiol Aging       Date:  2009-09-24       Impact factor: 4.673

10.  Sleep dysfunction in multiple system atrophy.

Authors:  Luigi Ferini-Strambi; Sara Marelli
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.